Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098191 | 0.85 | FGFR1 (0.38) | CHEK1MAP4K4CSF1RPRKACAKDR | |
| SCHEMBL4602967 | 0.76 | ALK (0.38) | MAP3K14CHEK1MAP4K4CSF1RPRKACA | |
| SCHEMBL1417158 | 0.72 | KDM4E (0.55) | CHEK1MAP4K4CSF1RPRKACAKDR | |
| SCHEMBL29965863 | 0.72 | KDM4E (0.55) | CHEK1MAP4K4CSF1RPRKACAKDR | |
| SCHEMBL4585307 | 0.72 | ADORA3 (0.35) | — | |
| SCHEMBL30973180 | 0.71 | MAPK8 (0.47) | — | |
| SCHEMBL9038736 | 0.69 | KDM4E (0.47) | CHEK1MAP4K4CSF1RPRKACAKDR | |
| SCHEMBL30641711 | 0.68 | DYRK1A (0.34) | CHEK1MAP4K4CSF1RPRKACAKDR | |
| SCHEMBL5695722 | 0.66 | DYRK1A (0.47) | MAP3K14DYRK1ADYRK1B | |
| SCHEMBL11413815 | 0.64 | FGFR1 (0.44) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261974-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2008-10-23 | — | — | US | disclosed |
| EP-1940812-A2 | NOVEL CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007038331-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261974-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | MAP3K14 151/4885CHEK1 1299/4885MAP4K4 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.